has been cited by the following article(s):
[1]
|
Clinical and economic assessment of nusinersen: the Bulgarian perspective
Expert Opinion on Orphan Drugs,
2020
DOI:10.1080/21678707.2020.1835641
|
|
|
[2]
|
Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles
Expert Opinion on Orphan Drugs,
2017
DOI:10.1080/21678707.2018.1421063
|
|
|